Amicus Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
Amicus Therapeutics Inc. believes it can rescue enzymes and other proteins containing mutations that result in misfolding, to restore their normal function and intervene in disease states. It's developing therapeutics for certain orphan indications, and plans to expand into other indications in which a genetic mutation results in sub-normal protein expression.